ID: h-a3167806d3
Hypothesis
NAD+-SIRT1-H3K9me3 restoration enables true senescence reversal, while incomplete metabolic reprogramming only suppresses SASP without growth arrest reversal
Partial metabolic interventions (e.g., mTOR inhibition alone) suppress SASP secretion but leave growth arrest intact because they fail to restore epigenetic architecture at senescence-associated heterochromatin foci (SAHF).
cell biology
EvidencePending (0%)📖 5 cit🗣 1 debates✓ 5 support✗ 2 oppose
✓ All Quality Gates Passed
🧪 Overview
Partial metabolic interventions (e.g., mTOR inhibition alone) suppress SASP secretion but leave growth arrest intact because they fail to restore epigenetic architecture at senescence-associated heterochromatin foci (SAHF). Complete NAD+ restoration activates SIRT1, which deacetylates H3K9 and recruits SUV39H1/HP1 to re-establish heterochromatin, allowing silencing of p16INK4a and re-expression of E2F-target proliferation genes. This predicts that single-agent senolytics or mTOR inhibitors halt neurodegeneration-associated senescence progression, but combinatorial NAD+ boosting with SIRT1 activation achieves true reversal of established senescent phenotypes in neurons and glia.
🧬 Mechanism
🧬 Curated Mechanism Pathway
Curated pathway from expert analysis
flowchart TD
A["NAD+ Restoration<br/>SIRT1 Activation"]
B["H3K9me3<br/>Epigenetic Reset"]
C["Senescence Reversal<br/>Growth Arrest Relief"]
D["Incomplete Metabolic<br/>Reprogramming Caveat"]
E["SASP Suppression<br/>without Growth Arrest"]
F["SIRT1 as<br/>NAD+-Sirtuin Target"]
A --> B
B --> C
C --> D
D --> E
E --> F
style A fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style F fill:#1b5e20,stroke:#a5d6a7,color:#a5d6a7⚖️ Evidence
⚖️ Evidence Matrix5 supports2 contradicts
Supports
Novel Role of the SIRT1 in Endocrine and Metabolic Diseases.
Contradicts
Nicotinamide riboside supplementation raises systemic NAD+ and shows cognitive benefits in mild cognitive impairment but does not demonstrate reversal of senescence biomarkers (p16, gamma-H2AX, SASP) in brain tissue, suggesting NAD+ restoration may attenuate rather than reverse neuronal senescence
PMID:41357333moderate
Contradicts
SIRT1 activators reduce SASP and extend healthspan but comprehensive reviews confirm SIRT1 cannot fully reverse established growth arrest; H3K9me3 restoration at SAHFs requires cooperative epigenetic remodeling beyond SIRT1 activity alone
PMID:41934491moderate
📖 Linked Papers
No linked papers recorded for this hypothesis yet.
🏥 Translation
🧬 3D Protein Structure — SIRT1
🧠 GTEx v10 Brain ExpressionJSON
Median TPM across 13 brain regions for SIRT1 from GTEx v10.
💉 Clinical Trials
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for SIRT1.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
🏆 Tournament
🏆 Arenas / Elo
No arena matches recorded yet. Browse Arenas →
📊 Market Indicators
7d Trend
↔
Stable
7d Momentum
▲ 0.0%
Volatility
High
0.0861
Events (7d)
1
Price History
▲9.8%💾 Resource Usage
LLM Tokens
15,232
$0.0914
Total Cost
$0.0914
🔮 Predictions
🔎 Predictions vs Observations2 predictions · 0 with recorded observations
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF 5xFAD mice (n=20/genotype) receive dietary nicotinamide riboside supplementation (1200mg/kg chow) combined with SRT2104 (30mg/kg/day ip) from 9-12 months of age THEN spatial memory reversal (Barnes | NR+SRT2104 treated 5xFAD mice will exhibit both reversal of established cognitive deficits and reduction in p16INK4a+ senescent neurons, while rapamycin-treated | — no observation — | pending | 0.55 |
| IF human iPSC-derived neurons carrying familial AD mutations are treated with nicotinamide riboside (NR, 1mM) + SIRT1 activator (SRT2104, 1μM) for 14 days THEN a composite senescence reversal score (p | Combinatorial NAD+ boosting with SIRT1 activation will achieve ≥60% reduction in p16INK4a mRNA, ≥2-fold increase in H3K9me3 ChIP signal at CDKN2A promoter, and | — no observation — | pending | 0.62 |
🔮 Falsifiable Predictions (2)
pendingconf 62%
IF human iPSC-derived neurons carrying familial AD mutations are treated with nicotinamide riboside (NR, 1mM) + SIRT1 activator (SRT2104, 1μM) for 14 days THEN a composite senescence reversal score (p16INK4a reduction ≥60%, H3K9me3 enrichment at CDKN2A locus ≥2-fold, EdU incorporation recovery ≥30%
Predicted outcome: Combinatorial NAD+ boosting with SIRT1 activation will achieve ≥60% reduction in p16INK4a mRNA, ≥2-fold increase in H3K9me3 ChIP signal at CDKN2A prom
Falsification: If rapamycin monotherapy produces equivalent growth arrest reversal (p16INK4a reduction ≥60% OR EdU recovery ≥30%) to NR+SRT2104 without NAD+ restoration, the hypothesis that incomplete metabolic repr
pendingconf 55%
IF 5xFAD mice (n=20/genotype) receive dietary nicotinamide riboside supplementation (1200mg/kg chow) combined with SRT2104 (30mg/kg/day ip) from 9-12 months of age THEN spatial memory reversal (Barnes maze latency ≥40% improvement vs. 9-month baseline, matching 3-month-old controls) will correlate w
Predicted outcome: NR+SRT2104 treated 5xFAD mice will exhibit both reversal of established cognitive deficits and reduction in p16INK4a+ senescent neurons, while rapamyc
Falsification: If rapamycin treatment alone achieves ≥40% improvement in Barnes maze latency matching the NR+SRT2104 group, or if NR+SRT2104 fails to reduce p16INK4a+ cell counts while producing cognitive improvemen
▸Metadatasource: v1_phase_c_backfill · origin_type: audit_hypothesis_generator
| source | v1_phase_c_backfill |
| origin_type | audit_hypothesis_generator |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.